



Genetics-inspired Therapeutics for Pulmonary Hypertension

A PVRI Symposium

2 June 2026

Royal College of Physicians, London



Programme

08:00 - 09:00 **Registration and refreshments**

09:00 - 09:05 **Welcome**
Brad Maron, University of Maryland

Genetic insights into pulmonary vascular disease

Chairs: Stefan Graf, University of Cambridge; Micheala Aldred, Indiana University; Laura Southgate, University of London

09:05 - 09:30 **Overview of genetics in PH & hereditary
haemorrhagic telangiectasia**
Richard Trembath, King's College London

09:30 - 09:50 **Genetics of the right ventricle**
Lars Harbaum, Universitätsklinikum Hamburg-Eppendorf

09:50 - 10:00 **Q&A**

Therapeutic agents targeting TGF- β /BMP pathway: Part 1

Chairs: Brad Maron, University of Maryland & Luke Howard, Imperial College Healthcare NHS Trust

10:05 - 10:25 **Overview of TGF β -BMP pathway**
Marie-Jose Goumans, Leiden University

10:25 - 10:45 **Biology behind the PAH – HHT overlap**
Wei Li, University Of Cambridge

10:45 - 11:15 **Refreshment break**

11:15 - 11:35 **Sotatercept – overview of clinical experience**
Ardi Ghofrani, Justus-Liebig-Universität Gießen

11:35 - 11:55 **Sotatercept – deep phenotyping the cardiac
response**
Khodr Tello, Justus-Liebig-Universität Gießen

11:55 - 12:15 **Sotatercept – what can we learn from the
biological response**
Paul Yu, Mass General Brigham

12:15 - 12:30 **Discussion**

12:30 - 13:30 **Buffet lunch**

Therapeutic agents targeting TGF- β /BMP pathway: Part 2

Chairs: Jane Leopold, Harvard University and Nick Morrell, University of Cambridge

13:30 - 13:50 **Inhibiting BMP9**
Kevin Hart, Pfizer

13:50 - 14:10 **HS235, a Next-Generation BMP-9/-10 Sparing
Activin Signaling Inhibitor**
Maureen O'Connor, 35Pharma

14:10 - 14:30 **LTP001 study**
Alex Rothman, The University of Sheffield and
Ana-Maria Tanase, Novartis

14:30 - 14:50 **Alk1:BMPRII agonism via bispecific clustering
antibody for the treatment of HHT & PAH**
Patrick Andre, Diagonal Therapeutics

14:50 - 15:10 **Modulating TGF- β signalling for pulmonary
hypertension and HHT**
Nick Morrell, Interact Bio

15:10 - 15:30 **Q & A**

15:30 - 16:00 **Refreshment break**

Developing therapeutic agents to target other genetically validated pathways

Chairs: TBC

16:00 - 16:15 **Targeting ZIP12**
Rachel Gurrell, Apollo Therapeutics

16:15 - 16:30 **Sox17**
Chris Rhodes, Imperial College London

16:30 - 17:00 **Discussion: What information should we be
collecting from clinical trials to better inform
drug development in this space?**

17:00 - 18:30 **Networking reception**
